Benzylpenicilloyl-specific immunoglobulin E (BPO-specific IgE) (BPO-specific IgE)

Benzylpenicilloyl-specific immunoglobulin E (IgE) antibodies are the primary immunological mediators of immediate (Type I) hypersensitivity reactions to penicillin G and related beta-lactams (StatPearls, 2023). The benzylpenicilloyl (BPO) moiety is characterized as the "major determinant" of penicillin allergy because approximately 95% of penicillin molecules degrade into this form, which then covalently binds to host proteins to create a hapten-protein complex (NIH, 2022). These specific IgE antibodies are typically bound to high-affinity receptors on the surface of mast cells and basophils. When a sensitized individual is re-exposed to penicillin, the BPO-protein complex cross-links these IgE antibodies, leading to cellular degranulation and the systemic release of inflammatory mediators like histamine and leukotrienes. This physiological response can manifest as urticaria, angioedema, or life-threatening anaphylaxis. Diagnostic agents such as benzylpenicilloyl polylysine are used to detect these antibodies via skin testing, while therapeutic interventions like omalizumab may be used to sequester IgE and prevent the allergic cascade (PubMed, 2020).

Other names

Anti-benzylpenicilloyl IgEPenicillin G-specific IgEMajor determinant-specific IgEBPO-IgE

Diagnostic agents like benzylpenicilloyl polylysine bind to and cross-link BPO-specific IgE on mast cells to induce a localized wheal-and-flare reaction for allergy confirmation (FDA, 2013). Therapeutic monoclonal antibodies like omalizumab bind to the Fc region of the IgE molecule, preventing it from attaching to mast cells and basophils, thereby inhibiting the allergic response (PubMed, 2020).